NasdaqCM - Delayed Quote USD

Altamira Therapeutics Ltd. (CYTO)

1.4300 -0.0600 (-4.03%)
At close: June 7 at 4:00 PM EDT
Currency in CHF All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Cost of Revenue
--
--
1,443.8550
2,240.5540
--
--
Gross Profit
--
--
-1,138.2390
-2,176.6720
--
--
Operating Expense
5,916.1000
5,916.1000
18,013.9180
6,871.3500
5,283.1660
--
Operating Income
-5,916.1000
-5,916.1000
-18,013.9180
-6,871.3500
-5,283.1660
--
Net Non Operating Interest Income Expense
-730.1950
-730.1950
-791.2140
12.8780
-134.8930
--
Other Income Expense
-623.7440
-623.7440
145.5710
52.2460
-2,803.3900
--
Pretax Income
-7,270.0380
-7,270.0380
-18,659.5620
-6,806.2260
-8,221.4490
--
Tax Provision
--
--
-7.9190
-117.9450
-21.2840
--
Net Income Common Stockholders
-3,869.1730
-3,869.1730
-26,528.4110
-17,058.4430
-8,200.1650
--
Diluted NI Available to Com Stockholders
-3,869.1730
-3,869.1730
-26,528.4110
-17,058.4430
-8,200.1650
--
Basic EPS
-7.88
-7.88
-582.58
-515.11
-505.40
--
Diluted EPS
-7.88
-7.88
-582.58
-515.11
-505.40
--
Basic Average Shares
491.2580
491.2580
45.5360
33.1160
15.0350
--
Diluted Average Shares
491.2580
491.2580
45.5360
33.1160
15.0350
--
Total Operating Income as Reported
-5,916.0990
-5,916.0990
-18,013.9190
-6,871.3500
-5,283.1660
--
Rent Expense Supplemental
15.7050
15.7050
6.0010
52.2800
13.8710
--
Total Expenses
5,916.1000
5,916.1000
18,013.9180
6,871.3500
5,283.1660
--
Net Income from Continuing & Discontinued Operation
-3,869.1730
-3,869.1730
-26,528.4110
-17,058.4430
-8,200.1650
--
Normalized Income
-6,685.8510
-6,685.8510
-18,797.1522
-6,739.6216
-5,735.9852
--
Interest Income
302.2490
302.2490
114.2680
26.9900
0.2580
--
Interest Expense
1,032.4440
1,032.4440
904.3450
14.1120
135.1510
--
Net Interest Income
-730.1950
-730.1950
-791.2140
12.8780
-134.8930
--
EBIT
-6,237.5940
-6,237.5940
-17,755.2170
-6,792.1140
-8,086.2980
--
EBITDA
-6,118.2900
-6,118.2900
-17,636.3300
-6,715.7570
-8,066.2620
--
Reconciled Cost of Revenue
--
--
1,443.8550
2,193.9190
--
--
Reconciled Depreciation
119.3040
119.3040
118.8870
76.3570
20.0360
--
Net Income from Continuing Operation Net Minority Interest
-7,270.0380
-7,270.0380
-18,651.6430
-6,688.2810
-8,200.1650
--
Total Unusual Items Excluding Goodwill
-584.1870
-584.1870
145.5710
52.2460
-2,803.3900
--
Total Unusual Items
-584.1870
-584.1870
145.5710
52.2460
-2,803.3900
--
Normalized EBITDA
-5,534.1030
-5,534.1030
-17,781.9010
-6,768.0030
-5,262.8720
--
Tax Rate for Calcs
--
--
0.0000
0.0000
0.0001
--
Tax Effect of Unusual Items
--
--
0.0618
0.9054
-339.2102
--
12/31/2019 - 8/6/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CDIO Cardio Diagnostics Holdings, Inc.
0.6774
-0.59%
 
DRMA Dermata Therapeutics, Inc.
3.3000
-5.44%
 
ENSC Ensysce Biosciences, Inc.
0.5455
+0.06%
 
PALI Palisade Bio, Inc.
4.5700
-2.56%
 
ENVB Enveric Biosciences, Inc.
0.7600
+1.06%
 
ALLR Allarity Therapeutics, Inc.
0.5010
-9.71%
 
LGVN Longeveron Inc.
1.0400
-0.95%
 
SONN Sonnet BioTherapeutics Holdings, Inc.
1.7000
+2.41%
 
BDRX Biodexa Pharmaceuticals Plc
0.9391
-5.94%
 
CING Cingulate Inc.
0.7228
+0.67%